Agonist antibodies that bind human cd137 and uses thereof
AssigneeCompass Therapeutics LLC
InventorsPiotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
Claims19
A method of treating cancer in a subject by inducing or enhancing an anti-tumor immune response, comprising administering to the subject an isolated monoclonal antibody, or antigen binding portion thereof, that specifically binds human CD137, wherein the antibody or antigen binding portion thereof comprises heavy chain CDR1, CDR2 and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 48, 56 and 68, respectively, and light chain CDR1, CDR2 and CDR3 comprising the amino acid sequences of SEQ ID NOs:
- 69, 78 and 89, respectively, thereby treating cancer in the subject by inducing or enhancing an anti-tumor immune response.
A method of treating cancer in a subject by inducing or enhancing an anti-tumor immune response, comprising administering to the subject an isolated monoclonal antibody, or antigen binding portion thereof, that specifically binds human CD137, wherein the antibody or antigen binding portion thereof comprises heavy and light chain variable regions comprising the amino acid sequences of SEQ ID NOs:
- 4 and 6, respectively, thereby treating cancer in the subject by inducing or enhancing an anti-tumor immune response.
A method of treating cancer in a subject by inducing or enhancing an anti-tumor immune response, comprising administering to the subject an isolated monoclonal antibody that specifically binds human CD137, wherein the antibody comprises heavy and light chains comprising the amino acid sequences of SEQ ID NOs:
- 129 and 133, respectively, thereby treating cancer in the subject by inducing or enhancing an anti-tumor immune response.
Dependencies are inferred from the claim text.